In our previous work, the large next generation sequencing screening of proximal promotor regions of 19 genes encoding SLC (n = 15) and ABC (n = 4) transporters with annotated function of drug transporters revealed that SNP rs460089 (located in the promotor region of SLC22A4) is significantly associated with response to imatinib first line therapy in CML patients in the European population [14]. This evidence concerns the gene SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive.